...
首页> 外文期刊>Biotechnology Advances: An International Review Journal >Standardizing CAR-T therapy: Getting it scaled up
【24h】

Standardizing CAR-T therapy: Getting it scaled up

机译:标准化Car-T治疗:缩小了

获取原文
获取原文并翻译 | 示例
           

摘要

CAR-T therapy, grafting the specificity of a monoclonal antibody onto a T cell to target certain cancer cells, has been recognized as a promising therapeutic approach for cancer control as evidenced by the two CAR-T products proved by FDA in 2017. However, the unique heterogeneity of CAR-T therapy has restricted its production in a limited number of institutions and made it a boutique oncotherapy. By reviewing outstanding issues surrounding the commercial scale production of CAR-T therapy, we conclude that achieving mass production of CAR-T therapy without sacrificing its personalized nature is a worldwild challenge for making CAR-T a key element in the next generation of precision medicine, which can be achieved by standardizing 7 prominent factors that collectively determine the scale of CAR-T manufacturing.
机译:Car-T治疗,接枝单克隆抗体对T细胞的特异性以靶向某些癌细胞,已被认为是2017年FDA证明的两种Car-T产品所证明的癌症控制的有希望的治疗方法。然而, Car-T治疗的独特异质性限制了其在有限数量的机构中的生产,并使其成为精品疗法。 通过审查围绕商业规模生产的卓越问题,我们得出结论,在不牺牲其个性化性质的情况下,实现批量生产的汽车-T治疗是在下一代精密医学中制作CAR-T一个关键因素的全球挑战 ,这可以通过标准化7个突出因素来实现,这些因素集体确定汽车-T制造规模。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号